Engineers Gate Manager LP Sells 243,693 Shares of uniQure N.V. $QURE

Engineers Gate Manager LP trimmed its stake in uniQure N.V. (NASDAQ:QURE) by 81.3% in the second quarter, HoldingsChannel.com reports. The firm owned 56,064 shares of the biotechnology company’s stock after selling 243,693 shares during the period. Engineers Gate Manager LP’s holdings in uniQure were worth $2,582,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. IFP Advisors Inc lifted its holdings in uniQure by 39.8% during the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock worth $128,000 after buying an additional 791 shares during the period. Mraz Amerine & Associates Inc. acquired a new stake in shares of uniQure in the second quarter valued at about $390,000. Arizona State Retirement System increased its stake in shares of uniQure by 17.7% in the second quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company’s stock valued at $596,000 after buying an additional 1,942 shares during the period. California State Teachers Retirement System raised its position in shares of uniQure by 6,641.2% during the second quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock worth $111,615,000 after acquiring an additional 2,387,316 shares during the last quarter. Finally, Syon Capital LLC bought a new position in shares of uniQure during the second quarter worth about $279,000. 78.83% of the stock is owned by institutional investors.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 21,167 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the transaction, the director owned 25,996 shares in the company, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the sale, the director owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 332,175 shares of company stock valued at $15,289,008. Company insiders own 4.65% of the company’s stock.

uniQure Price Performance

uniQure stock opened at $44.93 on Tuesday. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of -11.20 and a beta of 0.94. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The stock’s 50 day moving average price is $44.43 and its two-hundred day moving average price is $31.31.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the prior year, the firm earned ($0.69) EPS. On average, equities analysts predict that uniQure N.V. will post -3.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on QURE. Mizuho upped their target price on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Leerink Partners raised their price target on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. William Blair initiated coverage on shares of uniQure in a research report on Wednesday, September 2nd. They issued an “outperform” rating on the stock. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research report on Wednesday, June 17th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $65.00.

uniQure Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure’s pipeline has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.